Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Clinical trial NCT04229979 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04229979
- Sponsor
- Sellas Life Sciences Group
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-08
- Primary completion
- 2025-12-01
- Enrollment
- 127
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.